Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.74 - $46.00
Previous CloseN/A
Volume41.45K
Average Volume (3M)1.27M
Market Cap
$2.34B
Enterprise Value$2.10B
Total Cash (Recent Filing)$549.63M
Total Debt (Recent Filing)$8.68M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 11, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding76,733,600
10 Day Avg. Volume806,831
30 Day Avg. Volume1,266,497
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue279.87
Enterprise Value/Gross Profit-3.19K
Enterprise Value/Ebitda-7.21
Forecast
1Y Price Target
$55.64Price Target Upside82.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Drug EfficacyAzetukalner is positioned to become a mainstay in refractory focal epilepsy due to its compelling Phase 2 data and mood stabilization effect.
Market PositioningAzetukalner is nicely positioned to capture significant share as a second-line therapy given its efficacy, mood benefits, and ease-of-use, in contrast to first-line therapies with mood liabilities.
Bears Say
Adverse EffectsVisual hallucinations were noted in 14% of participants, which is significantly higher compared to 2% in ezogabine's label.
Clinical Trial DelaysThe delay of the X-TOLE2 data in focal onset seizures (FOS) to early 2026 is disappointing, especially with other studies enrolling more rapidly.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $46.00 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $2.34B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Aug 11, 2025 which is in 6 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on May 12, 2025. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$0.896 by $0.066.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -0.99.
How many shares outstanding does Xenon have?
Xenon has 76,733,600 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$0.83 in its last earnings report, beating expectations of -$0.896. Following the earnings report the stock price went down -17.434%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.64 (82.43% Upside)
$55.64 (82.43% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 613.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.4 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.25%
12-Months-Change
Fundamentals
Return on Equity
-31.60%
Trailing 12-Months
Asset Growth
-19.12%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicated significant progress across Xenon's pipeline, particularly with azetukalner in epilepsy and MDD. Financially, the company is well-positioned to support ongoing developments. Despite a slight delay in the X-TOLE2 study and a negative primary endpoint in the MDD study, the overall sentiment remains positive due to consistent progress and strong financial backing.Read More>XENE Stock 12 Month Forecast
Average Price Target
$55.64
▲(82.43%Upside)
Technical Analysis
Merus
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
MoonLake Immunotherapeutics
―
Ownership Overview
0.14% Insiders
29.60% Mutual Funds
0.62% Other Institutional Investors
63.40% Public Companies and
Individual Investors